Compare Neurocrine Biosciences Inc (NBIX) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Nucor Corporation — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Nucor Corporation trades at $257.08 (market cap $58.17B). The key difference: Nucor Corporation is far larger — about 3.7× Neurocrine Biosciences Inc's market cap, and Nucor Corporation pays a 0.87% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NUE | |
|---|---|---|
Market Cap | $15.77B | $58.17B |
Sector | Health | Basic Materials |
52-Week High | $185.50 | $274.74 |
52-Week Low | $123.10 | $131.78 |
Enterprise Value | $15.78B | $62.58B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Nucor Corporation (NUE) trades at $256.40, down 1.79% on the day, with a bullish technical signal supported by moving averages and strong institutional interest. The company shows improving fundamentals with recent earnings beats (Q1 and Q2 2026) and projected revenue growth to $36.1B in 2026. Analyst consensus remains positive with a $277.57 price target, though recent trade tensions and cyclical steel industry challenges present headwinds.
NUE offers value with reasonable valuation multiples (P/E 20.46, P/S 1.63) and strong profitability metrics (ROE 13.52%). Key risks include exposure to steel price volatility and macroeconomic sensitivity, but infrastructure demand and tariff protections provide tailwinds. Institutional accumulation and dividend stability support the investment case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
